After years of stagnation, a paradigm shift has occurred in the therapy of hepatobiliary malignancies: immune-oncology based combinations and new options in the second line revolutionized the treatment of patients with hepatocellular carcinoma, while biliary cancers – endowed with a genuinely high frequency of targetable lesions – evolved as a role model for precision oncology. These developments have generated a growing need for clinicians, pathologists and translational scientists to gain an in-depth understanding of diagnostic and clinical strategies that facilitate the implementation of individualized treatment concepts in hepato-oncology. The EASL school on “Personalized medicine in hepatobiliary malignancies” transitions fluently between molecular pathology diagnostics and clinical translation and provides room and space to foster interdisciplinary exchange. Under the guidance of experts in the field (liver pathologists, clinical and basic hepato-oncologists), students will gain confidence in the interpretation of molecular diagnostics reports and perform group work to build innovative treatment concepts for patients with hepatobiliary cancers. In addition to short lectures, panel discussions and a “live microscopy session”, the school features thought-provoking discourses on the diagnostic and therapeutic future of hepato-oncology.

School Organisers: Thomas Longerich, Anna Saborowski, Peter Schirmacher, and Arndt Vogel.

• Understand the technological basis, potential and restriction of modern molecular pathology diagnostics in order to make optimal use of it in clinical practice.
• Know the current and upcoming treatment options and strategies for hepatobiliary malignancies.
• Comprehend the elements of innovative molecularly guided therapy (molecularly guided and basket clinical trials, molecular tumor board, evidence levels and evidence generation for personalized approaches, off-label concepts, etc.).
• Gain a basic understanding of critical regulatory considerations associated with personalized medicine.
• Understand the interdisciplinary nature of treatment concepts and the unmet needs in biomarker development, translation and clinical practice of molecularly guided therapy.
• Discuss how to implement these exponentially growing innovations into daily medical practice.

• Hepatologists
• Basic and translational scientists
• Clinical scientists
• Pathologists
• Molecular pathologists

• Roadmap to navigate the complexities of molecular testing and interpretation of genetic alterations.
• Toolbox to provide “beyond state-of-the-art care” for patients with hepatobiliary malignancies.
• Networking with a multidisciplinary group of translational scientists and clinicians.